Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
CAMBRIDGE, Mass., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET.
马萨诸塞州剑桥，2025年1月3日（环球新闻）-- Agios Pharmaceuticals, Inc.（纳斯达克：AGIO），一家在细胞代谢和Pk激活领域的领导者，开创了针对罕见疾病的治疗方案，今天宣布其管理团队计划在2025年1月15日星期三上午7:30 PT / 上午10:30 ET于第43届摩根大通医疗会议上进行报告。
The live webcast will be accessible on the Investors section of the company's website () under the "Events & Presentations" tab. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation.
直播网络广播将在公司网站的投资者部分（）的“活动与演示”标签下提供访问。会议的重播将在公司网站上存档，至少保存两周。
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company's website at .
关于Agios
Agios是Pk激活的先锋领导者，致力于开发和提供改变患者生活的治疗方案，使他们能够应对罕见疾病。在美国，Agios为患有Pk缺乏症的成年人提供一种首创的丙酮酸激酶(PK)激活剂，这是该罕见、终身性和严重溶血性贫血的第一种改变疾病进程的治疗方案。基于公司在经典血液学领域的深厚科学专业知识以及在细胞代谢和罕见血液病领域的领导地位，Agios正在推进一条强大的临床研发管线，涉及α-和β-地中海贫血、镰状细胞病、小儿Pk缺乏症、骨髓异常综合征(MDS)相关贫血和苯丙酮尿症(PKU)的研究项目。除临床管线外，Agios还在推动一种前临床TMPRSS6 siRNA作为治疗真性红细胞增多症的潜在方案。更多信息，请访问公司的官方网站。
Contacts:
联系方式：
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com
投资者联系
克里斯·泰勒，副总裁，投资者关系和企业传播
agios pharmaceuticals
IR@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com
媒体联系人
Eamonn Nolan，高级企业通信董事
agios pharmaceuticals
Media@agios.com
